The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter
Abstract
BACKGROUND: The optimal upper limit of the normal range for prostate-specific antigen (PSA) is unknown. We investigated the prevalence of prostate cancer among men in the Prostate Cancer Prevention Trial who had a PSA level of 4.0 ng per milliliter or less. METHODS: Of 18,882 men enrolled in the prevention trial, 9459 were randomly assigned to receive placebo and had an annual measurement of PSA and a digital rectal examination. Among these 9459 men, 2950 men never had a PSA level of more than 4.0 ng per milliliter or an abnormal digital rectal examination, had a final PSA determination, and underwent a prostate biopsy after being in the study for seven years. RESULTS: Among the 2950 men (age range, 62 to 91 years), prostate cancer was diagnosed in 449 (15.2 percent); 67 of these 449 cancers (14.9 percent) had a Gleason score of 7 or higher. The prevalence of prostate cancer was 6.6 percent among men with a PSA level of up to 0.5 ng per milliliter, 10.1 percent among those with values of 0.6 to 1.0 ng per milliliter, 17.0 percent among those with values of 1.1 to 2.0 ng per milliliter, 23.9 percent among those with values of 2.1 to 3.0 ng per milliliter, and 26.9 percent among those with values of 3.1 to 4.0 ng per milliliter. The prevalence of high-grade cancers increased from 12.5 percent of cancers associated with a PSA level of 0.5 ng per milliliter or less to 25.0 percent of cancers associated with a PSA level of 3.1 to 4.0 ng per milliliter. CONCLUSIONS: Biopsy-detected prostate cancer, including high-grade cancers, is not rare among men with PSA levels of 4.0 ng per milliliter or less--levels generally thought to be in the normal range.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Influence of Finasteride on the Development of Prostate Cancer
Thompson, I. M., Goodman, P. J., Tangen, C. M., Lucia, M. S., Miller, G. J., Ford, L. G., Lieber, M. M., Cespedes, R. D., Atkins, J. N., Lippman, S. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030660 · Cited by 2,518
Self-citationMeasurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer
Catalona, W. J., Smith, D. S., Ratliff, T. L., Dodds, K. M., Coplen, D. E., Yuan, J. J. J., Petros, J. A., & Andriole, G. L. (1991) · New England Journal of Medicine · doi:10.1056/nejm199104253241702 · Cited by 2,361
Sathianathen, N. (2021) · 50 Studies Every Urologist Should Know · doi:10.1093/med/9780190655341.003.0002 · Cited by 2,080
Phases of Biomarker Development for Early Detection of Cancer
Pepe, M. S., Etzioni, R., Feng, Z., Potter, J. D., Thompson, M. L., Thornquist, M., Winget, M., & Yasui, Y. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1054 · Cited by 1,686
Purification of a Human Prostate Specific Antigen
Wang, M. C., Valenzuela, L. A., Murphy, G. P., & Chu, T. M. (2017) · Journal of Urology · doi:10.1016/j.juro.2016.10.100 · Cited by 825
Cooner, W. H., Mosley, B. R., Rutherford, C. L., Beard, J. H., Pond, H. S., Terry, W. J., Igel, T. C., & Kidd, D. D. (1990) · Journal of Urology · doi:10.1016/s0022-5347(17)40211-4 · Cited by 767
Albertsen, P. C. (1998) · JAMA · doi:10.1001/jama.280.11.975 · Cited by 717
Screening for Prostatic Carcinoma with Prostate Specific Antigen
Brawer, M. K., CHETNER, M. P., Beatie, J., Büchner, D. M., Vessella, R. L., & Lange, P. H. (1992) · The Journal of Urology · doi:10.1016/s0022-5347(17)37401-3 · Cited by 612
Gohagan, J. K., Prorok, P. C., Hayes, R. B., & Kramer, B.-S. (2000) · Controlled Clinical Trials · doi:10.1016/s0197-2456(00)00097-0 · Cited by 544
Punglia, R. S., D'Amico, A. V., Catalona, W. J., Roehl, K. A., & Kuntz, K. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021659 · Cited by 326
Research works printed but not linked: 16
- Wang MC, 1979, Invest Urol, 17, 159
- Brawley OW, 1998, Semin Urol Oncol, 16, 187
- 10.1002/(SICI)1097-0045(19990201)38:2<83::AID-PROS1>3.0.CO;2-B · DOI
- Thompson IM, 2003, World J Urol, 21, 28, 10.1007/s00345-002-0315-y · doi:10.1007/s00345-002-0315-y
- 10.1111/j.1464-410X.1987.tb09137.x · doi:10.1111/j.1464-410x.1987.tb09137.x
- Kuriyama M, 1980, Cancer Res, 40, 4658
- Liedtke RJ, 1984, Clin Chem, 30, 649, 10.1093/clinchem/30.5.649 · doi:10.1093/clinchem/30.5.649
- Yang N, 1984, Clin Chem, 30, 1057
- 10.1016/0090-4295(86)90146-9 · doi:10.1016/0090-4295(86)90146-9
- Kuriyama M, 1982, J Natl Cancer Inst, 68, 99
- Thompson IM, 1984, J Urol, 132, 690, 10.1016/S0022-5347(17)49828-4 · doi:10.1016/s0022-5347(17)49828-4
- Ruebush TK II, 1979, J Urol, 122, 492, 10.1016/S0022-5347(17)56477-0 · doi:10.1016/s0022-5347(17)56477-0
- 10.1016/S0022-5347(01)63951-X · doi:10.1016/s0022-5347(01)63951-x
- 10.1016/S0090-4295(96)00091-X · doi:10.1016/s0090-4295(96)00091-x
- 10.1093/jnci/90.16.1230 · doi:10.1093/jnci/90.16.1230
- 10.1016/S0140-6736(00)02269-8 · doi:10.1016/s0140-6736(00)02269-8
Cited by
EAU Guidelines on Prostate Cancer
Heidenreich, A., Aus, G., Bolla, M., Joniau, S., Matveev, V. B., Schmid, H. P., & Zattoni, F. (2008) · European Urology · doi:10.1016/j.eururo.2007.09.002 · Cited by 3,136
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-2-201207170-00459 · Cited by 2,522
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Heidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.09.046 · Cited by 1,936
Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00229 · Cited by 1,736
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Heidenreich, A., Bellmunt, J., Bolla, M., Joniau, S., Mason, M., Matveev, V., Mottet, N., Schmid, H.-P., van der Kwast, T., Wiegel, T., et al. (2011) · European Urology · doi:10.1016/j.eururo.2010.10.039 · Cited by 1,492
Early Detection of Prostate Cancer: AUA Guideline
Carter, H. B., Albertsen, P. C., Barry, M. J., Etzioni, R., Freedland, S. J., Greene, K. L., Holmberg, L., Kantoff, P., Konety, B. R., Murad, M. H., et al. (2013) · Journal of Urology · doi:10.1016/j.juro.2013.04.119 · Cited by 1,242
Label‐Free Impedance Biosensors: Opportunities and Challenges
Daniels, J. S., & Pourmand, N. (2007) · Electroanalysis · doi:10.1002/elan.200603855 · Cited by 1,192
20-Year Outcomes Following Conservative Management of Clinically Localized Prostate Cancer
Albertsen, P. C. (2005) · JAMA · doi:10.1001/jama.293.17.2095 · Cited by 1,187
Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brünner, N., Chan, D. W., Babaian, R., Bast, R. C., Dowell, B., Esteva, F. J., et al. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.105601 · Cited by 1,129
Androgen Deprivation Therapy for Prostate Cancer
Sharifi, N. (2005) · JAMA · doi:10.1001/jama.294.2.238 · Cited by 1,083
Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence
Chinen, A. B., Guan, C. M., Ferrer, J. R., Barnaby, S. N., Merkel, T. J., & Mirkin, C. A. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00321 · Cited by 1,032
Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial
Thompson, I. M., Ankerst, D. P., Chi, C., Goodman, P. J., Tangen, C. M., Lucia, M. S., Feng, Z., Parnes, H. L., & Coltman, C. A. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj131 · Cited by 938
Self-citationProstate-specific antigen and prostate cancer: prediction, detection and monitoring
Lilja, H., Ulmert, D., & Vickers, A. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2351 · Cited by 921
Thompson, I. M. (2005) · JAMA · doi:10.1001/jama.294.1.66 · Cited by 704
Self-citationA Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy
McKiernan, J., Donovan, M. J., O’Neill, V., Bentink, S., Noerholm, M., Belzer, S., Skog, J., Kattan, M. W., Partin, A., Andriole, G., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0097 · Cited by 674
Self-citationIlic, D., Djulbegovic, M., Jung, J. H., Hwang, E. C., Zhou, Q., Cleves, A., Agoritsas, T., & Dahm, P. (2018) · BMJ · doi:10.1136/bmj.k3519 · Cited by 641
Autoantibody Signatures in Prostate Cancer
Wang, X., Yu, J., Sreekumar, A., Varambally, S., Shen, R., Giacherio, D., Mehra, R., Montie, J. E., Pienta, K. J., Sanda, M. G., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051931 · Cited by 582
APTIMA PCA3 Molecular Urine Test: Development of a Method to Aid in the Diagnosis of Prostate Cancer
Groskopf, J., Aubin, S. M., Deras, I. L., Blase, A., Bodrug, S., Clark, C., Brentano, S., Mathis, J., Pham, J., Meyer, T., et al. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2005.063289 · Cited by 529
Prostate‐specific antigen: A review of the validation of the most commonly used cancer biomarker
Hernández, J., & Thompson, I. M. (2004) · Cancer · doi:10.1002/cncr.20480 · Cited by 527
Self-citationSkeletal PET with18F-Fluoride: Applying New Technology to an Old Tracer
Grant, F. D., Fahey, F. H., Packard, A. B., Davis, R. T., Alavi, A., & Treves, S. T. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.037200 · Cited by 520
Prostate Specific Antigen Best Practice Statement: 2009 Update
Greene, K. L., Albertsen, P. C., Babaian, R. J., Carter, H. B., Gann, P. H., Han, M., Kuban, D. A., Sartor, A. O., Stanford, J. L., Zietman, A., et al. (2009) · Journal of Urology · doi:10.1016/j.juro.2009.07.093 · Cited by 517
Rethinking Screening for Breast Cancer and Prostate Cancer
Esserman, L. (2009) · JAMA · doi:10.1001/jama.2009.1498 · Cited by 516
Noninvasive Coronary Angiography With Multislice Computed Tomography
Hoffmann, M. H. K. (2005) · JAMA · doi:10.1001/jama.293.20.2471 · Cited by 507
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
U.S. Preventive Services Task Force* (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-3-200808050-00008 · Cited by 505
Catalona, W. J., Partin, A. W., Sanda, M. G., Wei, J. T., Klee, G. G., Bangma, C. H., Slawin, K. M., Marks, L. S., Loeb, S., Broyles, D. L., et al. (2011) · Journal of Urology · doi:10.1016/j.juro.2010.12.032 · Cited by 502
Prevention and early detection of prostate cancer
Cuzick, J., Thorat, M. A., Andriole, G., Brawley, O. W., Brown, P. H., Culig, Z., Eeles, R. A., Ford, L. G., Hamdy, F. C., Holmberg, L., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70211-6 · Cited by 495
Self-citationMakarov, D. V., Trock, B. J., Humphreys, E. B., Mangold, L. A., Walsh, P. C., Epstein, J. I., & Partin, A. W. (2007) · Urology · doi:10.1016/j.urology.2007.03.042 · Cited by 483
Beyond PSA: The Next Generation of Prostate Cancer Biomarkers
Prensner, J. R., Rubin, M. A., Wei, J. T., & Chinnaiyan, A. M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003180 · Cited by 472
A First-Generation Multiplex Biomarker Analysis of Urine for the Early Detection of Prostate Cancer
Laxman, B., Morris, D. S., Yu, J., Siddiqui, J., Cao, J., Mehra, R., Lonigro, R. J., Tsodikov, A., Wei, J. T., Tomlins, S. A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3224 · Cited by 409
When effect sizes disagree: The case of r and d.
McGrath, R. E., & Meyer, G. J. (2006) · Psychological Methods · doi:10.1037/1082-989x.11.4.386 · Cited by 399
Multiparametric MRI for prostate cancer diagnosis: current status and future directions
Stabile, A., Giganti, F., Rosenkrantz, A. B., Taneja, S. S., Villeirs, G., Gill, I. S., Allen, C., Emberton, M., Moore, C. M., & Kasivisvanathan, V. (2020) · Nature Reviews Urology · doi:10.1038/s41585-019-0212-4 · Cited by 398
ETS Gene Fusions in Prostate Cancer: From Discovery to Daily Clinical Practice
Tomlins, S. A., Bjartell, A., Chinnaiyan, A. M., Jenster, G., Nam, R. K., Rubin, M. A., & Schalken, J. A. (2009) · European Urology · doi:10.1016/j.eururo.2009.04.036 · Cited by 381
Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker–Based Risk Score
Van Neste, L., Hendriks, R. J., Dijkstra, S., Trooskens, G., Cornel, E. B., Jannink, S. A., de Jong, H., Hessels, D., Smit, F. P., Melchers, W. J. G., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.04.012 · Cited by 370
Screening for Prostate Cancer With the Prostate-Specific Antigen Test: A Review of Current Evidence
Hayes, J. H., & Barry, M. J. (2014) · JAMA · doi:10.1001/jama.2014.2085 · Cited by 361
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
Lippman, S. M., Goodman, P. J., Klein, E. A., Parnes, H. L., Thompson, I. M., Kristal, A. R., Santella, R. M., Probstfield, J. L., Moinpour, C. M., Albanes, D., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji009 · Cited by 356
Self-citationActive Surveillance for Prostate Cancer: For Whom?
Klotz, L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3134 · Cited by 353
Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA
Tomlins, S. A., Aubin, S. M. J., Siddiqui, J., Lonigro, R. J., Sefton-Miller, L., Miick, S., Williamsen, S., Hodge, P., Meinke, J., Blase, A., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001970 · Cited by 350
Semmes, O. J., Feng, Z., Adam, B.-L., Banez, L. L., Bigbee, W. L., Campos, D., Cazares, L. H., Chan, D. W., Grizzle, W. E., Izbicka, E., et al. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2004.038950 · Cited by 343
Self-citationCancer overdiagnosis: a biological challenge and clinical dilemma
Srivastava, S., Koay, E. J., Borowsky, A. D., De Marzo, A. M., Ghosh, S., Wagner, P. D., & Kramer, B. S. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0142-8 · Cited by 337
Paleček, E., Tkáč, J., Bartošík, M., Bertók, T., Ostatná, V., & Paleček, J. (2015) · Chemical Reviews · doi:10.1021/cr500279h · Cited by 319
Hillier, S. M., Maresca, K. P., Femia, F. J., Marquis, J. C., Foss, C. A., Nguyen, N., Zimmerman, C. N., Barrett, J. A., Eckelman, W. C., Pomper, M. G., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1682 · Cited by 316
Heneghan, H. M., Miller, N., Kelly, R., Newell, J., & Kerin, M. J. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0103 · Cited by 315
Ren, S., Wang, F., Shen, J., Sun, Y., Xu, W., Lu, J., Wei, M., Xu, C., Wu, C., Zhang, Z., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.04.026 · Cited by 312
Overview of Dynamic Contrast-Enhanced MRI in Prostate Cancer Diagnosis and Management
Verma, S., Turkbey, B., Muradyan, N., Rajesh, A., Cornud, F., Haider, M. A., Choyke, P. L., & Harisinghani, M. (2012) · American Journal of Roentgenology · doi:10.2214/ajr.12.8510 · Cited by 301
Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer
Gallagher, D. J., Gaudet, M. M., Pal, P., Kirchhoff, T., Balistreri, L., Vora, K., Bhatia, J., Stadler, Z., Fine, S. W., Reuter, V., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2871 · Cited by 301
PSA and beyond: alternative prostate cancer biomarkers
Saini, S. (2016) · Cellular Oncology · doi:10.1007/s13402-016-0268-6 · Cited by 295
Long-Term Survival of Participants in the Prostate Cancer Prevention Trial
Thompson, I. M., Goodman, P. J., Tangen, C. M., Parnes, H. L., Minasian, L. M., Godley, P. A., Lucia, M. S., & Ford, L. G. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215932 · Cited by 288
Self-citationOutcomes of Active Surveillance for Men With Intermediate-Risk Prostate Cancer
Cooperberg, M. R., Cowan, J. E., Hilton, J. F., Reese, A. C., Zaid, H. B., Porten, S. P., Shinohara, K., Meng, M. V., Greene, K. L., & Carroll, P. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.4252 · Cited by 283
Smith, R. A., Cokkinides, V., Brooks, D., Saslow, D., Shah, M., & Brawley, O. W. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20096 · Cited by 275
Novel diagnostic biomarkers for prostate cancer
Madu, C. O., & Lu, Y. (2010) · Journal of Cancer · doi:10.7150/jca.1.150 · Cited by 261
Advancements in MR Imaging of the Prostate: From Diagnosis to Interventions
Bonekamp, D., Jacobs, M. A., El-Khouli, R., Stoianovici, D., & Macura, K. J. (2011) · RadioGraphics · doi:10.1148/rg.313105139 · Cited by 254
Chernet, B. T., & Levin, M. (2013) · Disease Models & Mechanisms · doi:10.1242/dmm.010835 · Cited by 148
Exosomal Secretion of Cytoplasmic Prostate Cancer Xenograft-derived Proteins
Jansen, F. H., Krijgsveld, J., van Rijswijk, A., van den Bemd, G.-J., van den Berg, M. S., van Weerden, W. M., Willemsen, R., Dekker, L. J., Luider, T. M., & Jenster, G. (2009) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800443-mcp200 · Cited by 107
Andropause: is androgen replacement therapy indicated for the aging male?
Hijazi, R. A., & Cunningham, G. R. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104518 · Cited by 105
Xu, M., Evans, L., Bizzaro, C. L., Quaglia, F., Verrillo, C. E., Li, L., Stieglmaier, J., Schiewer, M. J., Languino, L. R., & Kelly, W. K. (2022) · Cancers · doi:10.3390/cancers14164034 · Cited by 61
Chapter 9: Options for Summarizing Medical Test Performance in the Absence of a “Gold Standard”
Trikalinos, T. A., & Balion, C. M. (2012) · Journal of General Internal Medicine · doi:10.1007/s11606-012-2031-7 · Cited by 59
“However, PSA levels are not elevated in as many as 15 % of individuals with prostate cancer, making PSA testing prone to misclassification error.(17) One explanation for these misclassifications (falsenegative results) is that obesity can reduce serum PSA levels.”
Background
Metadata
- Authors
- Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., Crowley, J. J., & Coltman, C. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-05-27
- Volume
- 350
- Issue
- 22
- Pages
- 2239-2246
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2140687262
- Cited by
- 2,446
- References
- 16
- FWCI
- 118.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.